Tesamorelin vs Semaglutide (injectable)
One has a narrow HIV-lipodystrophy VAT indication and the other obesity/diabetes evidence; compare populations and endpoints rather than 'belly fat' marketing.
| Attribute | Tesamorelin | Semaglutide (injectable) |
|---|---|---|
| Human evidence | Tesamorelin has strong evidence for its narrow HIV-associated abdominal-fat indication. A randomized HIV/NAFLD study also reduced liver fat substantially, while a small 2025 Phase II cognitive trial did not show significant between-group cognitive benefit. | Extensive Phase III evidence supports weight loss with regulated semaglutide. SELECT demonstrated cardiovascular benefit in a defined population, and STEP 9 showed improved knee-OA pain/function in adults with obesity. |
| Research focus | Excess abdominal visceral fat in adults with HIV and lipodystrophy | Obesity, weight management, cardiovascular outcomes, heart failure, osteoarthritis, type 2 diabetes |
| Regulatory status | FDA-licensed Egrifta formulations are indicated to reduce excess abdominal fat in adults with HIV and lipodystrophy; not a general weight-loss approval. | Wegovy (semaglutide) is authorised in the EU for weight management in defined adults and adolescents; authorisation and dosing are product-, route-, indication- and jurisdiction-specific. |
| Route / formulation | Research-market tesamorelin is not automatically equivalent to authorised Egrifta products. | Evidence for licensed pre-filled injection pens cannot establish identity, concentration, sterility or equivalence of unverified semaglutide vials or non-authorised products. |
Why these are compared
These compounds appear in the body composition / abdominal-fat interest evidence landscape, but they are not interchangeable. Tesamorelin is ghrh analogue peptide studied in excess abdominal visceral fat in adults with hiv and lipodystrophy; Semaglutide (injectable) is long-acting glp-1 receptor agonist peptide analogue studied in obesity, weight management, cardiovascular outcomes, heart failure, osteoarthritis, type 2 diabetes. The purpose of this page is to compare the evidence base, not to recommend one compound over another.
Evidence maturity
Tesamorelin: Approved narrow indication with additional randomized human metabolic evidence.
Semaglutide (injectable): Approved medicine — extensive multi-outcome evidence, formulation/indication specific.
The table above gives the fuller human-evidence, regulatory and formulation context. Open the individual profiles for study-level records, limitations and source provenance.
What this comparison can and cannot establish
Not therapeutically equivalent; no simple head-to-head basis. Cross-study comparisons can be distorted by differences in population, route, formulation, dose, duration and endpoint. WhichPeps therefore does not turn indirect comparisons into a treatment recommendation or name a winner. A well-designed head-to-head human trial using comparable populations and clinically relevant outcomes would reduce uncertainty.